2. Search Result
Search Result
Results for "

active caspase-3

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Fluorescent Dye

6

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124344
    Avenanthramide C

    		Interleukin Related Neurological Disease
    Avenanthramide C is an orally active avenanthramide that can be isolated from oat seeds. Avenanthramide C decreases the protein expression of cleaved caspase-3 and increases the expression of p-GSK3β(Ser9) and IL-10 levels. Avenanthramide C has the potential for the research of Alzheimer’s disease .
    Avenanthramide C
  • HY-12294A
    PEAQX tetrasodium hydrate
    5 Publications Verification

    NVP-AAM077 tetrasodium hydrate

    		 Apoptosis Caspase iGluR Neurological Disease
    PEAQX tetrasodium hydrate (NVP-AAM077 tetrasodium hydrate) is a tetrasodium hydrate of PEAQX (HY-12294). PEAQX tetrasodium hydrate is an orally active and selective NMDA antagonist, with IC50 values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX tetrasodium hydrate can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .
    PEAQX tetrasodium hydrate
  • HY-10396
    Emricasan
    Maximum Cited Publications
    36 Publications Verification

    PF 03491390; IDN-6556

    		 Caspase Flavivirus Infection Neurological Disease Cancer
    Emricasan (PF 03491390) is an orally active and irreversible pan-caspase inhibitor. Emricasan inhibits Zika virus (ZIKV)-induced increases in caspase-3 activity and protected human cortical neural progenitors .
    Emricasan
  • HY-B0621
    Triclabendazole
    4 Publications Verification

    CGA89317

    		 Parasite Caspase Bcl-2 Family PARP Pyroptosis Infection
    Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica .
    Triclabendazole
  • HY-124617A
    AMXT-1501 tetrahydrochloride
    5+ Cited Publications

    		 Apoptosis Inflammation/Immunology Cancer
    AMXT-1501 tetrahydrochloride is an orally active polyamine transport inhibitor. AMXT1501 blocks tumor growth in immunocompetent mice but not in athymic nude mice lacking T cells . Combination of DFMO and AMXT‐1501 induces caspase‐3 mediated apoptosis in NB cell lines .
    AMXT-1501 tetrahydrochloride
  • HY-124476
    Cystamine

    		Caspase Glutaminase Apoptosis Cancer
    Cystamine is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .
    Cystamine
  • HY-W020050
    Cystamine dihydrochloride

    		Caspase Glutaminase Apoptosis Neurological Disease Cancer
    Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .
    Cystamine dihydrochloride
  • HY-D1432
    FITC-C6-DEVD-FMK

    		Fluorescent Dye Cancer
    FITC-C6-DEVD-FMK, a fluorescently labeled caspase-3 inhibitor, can be used for detection of active caspase-3 in mammalian cells undergoing apoptosis. FITC-C6-DEVD-FMK provides a convenient means for sensitive detection of activated caspase-3 in living cells. Z-DEVD-FMK is a specific caspase-3 inhibitor .
    FITC-C6-DEVD-FMK
  • HY-12294
    PEAQX

    NVP-AAM077

    		 Caspase Apoptosis iGluR Neurological Disease
    PEAQX (NVP-AAM077) is an orally active and selective NMDA antagonist, with IC50 values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .
    PEAQX
  • HY-12352
    HJC0416

    		STAT Apoptosis Cancer
    HJC0416 is a potent and orally active STAT3 inhibitor. HJC0416 shows antiprolifeative activity and induces apoptosis. HJC0416 decreases the expression of p-STAT3 (Tyr-705), Cyclin D1 and increases the expression of cleaved caspase-3 protein. HJC0416 shows anti-tumor activity .
    HJC0416
  • HY-B0621R
    Triclabendazole (Standard)

    		Parasite Caspase Bcl-2 Family PARP Pyroptosis Infection
    Triclabendazole (Standard) is the analytical standard of Triclabendazole. This product is intended for research and analytical applications. Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica .
    Triclabendazole (Standard)
  • HY-10396A
    (2R,3S)-Emricasan

    (2R,3S)-PF 03491390; (2R,3S)-IDN-6556

    		 Caspase Flavivirus Infection Neurological Disease Cancer
    (2R,3S)-Emricasan ((2R,3S)-PF 03491390) is an isomer of Emricasan (HY-10396). Emricasan is an orally active and irreversible pan-caspase inhibitor. Emricasan inhibits Zika virus (ZIKV)-induced increases in caspase-3 activity and protected human cortical neural progenitors .
    (2R,3S)-Emricasan
  • HY-W020050S
    Cystamine-d8 dihydrochloride

    		Apoptosis Caspase Glutaminase Cancer
    Cystamine-d8 (dihydrochloride） is the deuterium labeled Cystamine (dihydrochloride）[1]. Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD)[2][3][4].
    Cystamine-d8 dihydrochloride
  • HY-N0265
    Asperosaponin VI
    2 Publications Verification

    		 Caspase Apoptosis Cardiovascular Disease
    Asperosaponin VI, A saponin component from Dipsacus asper, induces osteoblast differentiation through BMP‐2/p38 and ERK1/2 pathway . Asperosaponin Ⅵ inhibits apoptosis in hypoxia-induced cardiomyocyte by increasing the Bcl-2/Bax ratio and decreasing active caspase-3 expression, as well as enhancing of p-Akt and p-CREB .
    Asperosaponin VI
  • HY-10805
    Almorexant
    4 Publications Verification

    ACT 078573

    		 Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis Neurological Disease Endocrinology Cancer
    Almorexant (ACT 078573) is an orally active, potent and competitive dual orexin receptor antagonist, with Kd values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant totally blocked the intracellular Ca 2+ signal pathway. Almorexant stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis .
    Almorexant
  • HY-10805A
    Almorexant hydrochloride
    4 Publications Verification

    ACT 078573 hydrochloride

    		 Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis Neurological Disease Endocrinology Cancer
    Almorexant (ACT 078573) hydrochloride is an orally active, potent and competitive dual orexin receptor antagonist, with Kd values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant hydrochloride reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant hydrochloride totally blocked the intracellular Ca 2+ signal pathway. Almorexant hydrochloride stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis .
    Almorexant hydrochloride
  • HY-B0347
    Lacidipine
    1 Publications Verification

    		 Calcium Channel Reactive Oxygen Species Caspase Apoptosis Cardiovascular Disease
    Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) .
    Lacidipine
  • HY-117136
    AN-7

    		HDAC Caspase Bcl-2 Family Cancer
    AN-7 is an orally active histone deacetylase (HDAC) inhibitor that induces histone hyperacetylation and differentiation in vitro and in vivo, and inhibits the proliferation of human prostate 22Rv1 cancer cells. AN-7 can increase the expression of the pro-apoptotic protein Bax, reduce the expression of the anti-apoptotic protein Bcl-2, and promote apoptosis by activating caspase-3, and can be used in the study of prostate cancer .
    AN-7
  • HY-N0702
    Tenuifolin

    		Beta-secretase Cholinesterase (ChE) Neurological Disease
    Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD) .
    Tenuifolin
  • HY-118129
    Schisandronic acid

    Ganwuweizic acid

    		 PARP Apoptosis Cancer
    Schisandronic acid is a triterpenoid antioxidant and anticancer agent extracted from Schisandra chinensis, which has potent cytotoxicity against human breast cancer cells, especially MCF-7. Schisandronic acid induces apoptosis and reduces cell viability in a time-dependent manner (MCF-7, IC50=8.06 μM). Schisandronic acid can upregulate active caspase-3 expression and cleave PARP, reduce the generation of reactive oxygen species and exhibit antioxidant effects .
    Schisandronic acid
  • HY-137038
    N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride

    TLCK hydrochloride

    		 Caspase Ser/Thr Protease Cancer
    N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride (TLCK hydrochloride) is an irreversible inhibitor for serine protease, which inhibits trypsin and trypsin-like protease by alkylating histidine residues in their active site. N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride inhibits caspase-3, caspase-6 and caspase-7, with IC50s of 12.0, 54.5 and 19.3 μM, respectively. N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride induces apoptosis in cell HL-60, and inhibits the decrease in mitochondrial transmembrane potential during apoptosis .
    N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride
  • HY-N0265R
    Asperosaponin VI (Standard)

    		Caspase Apoptosis Cardiovascular Disease
    Asperosaponin VI (Standard) is the analytical standard of Asperosaponin VI. This product is intended for research and analytical applications. Asperosaponin VI, A saponin component from Dipsacus asper, induces osteoblast differentiation through BMP‐2/p38 and ERK1/2 pathway . Asperosaponin Ⅵ inhibits apoptosis in hypoxia-induced cardiomyocyte by increasing the Bcl-2/Bax ratio and decreasing active caspase-3 expression, as well as enhancing of p-Akt and p-CREB .
    Asperosaponin VI (Standard)
  • HY-126741
    Azadirachtin
    2 Publications Verification

    		 Apoptosis Parasite NF-κB Bcl-2 Family Caspase Infection Inflammation/Immunology Cancer
    Azadirachtin is an oral active triterpenoid compound with anticancer, antimalarial, anti-inflammatory, and insecticidal activities. Azadirachtin induces cell apoptosis through the mitochondrial pathway (by inhibiting Bcl-2/Bax ratio or activating Apaf-1 and caspase-3) or through death receptors (by inhibiting TNFR activation). Additionally, Azadirachtin exerts its anti-inflammatory effects by inhibiting NF-кB signaling pathway activation, and it exhibits insecticidal activity by inducing apoptosis in insect cells .
    Azadirachtin
  • HY-151443
    HDAC-IN-47

    		HDAC Cancer
    HDAC-IN-47 is an orally active inhibitor of histone deacetylase (HDAC), with IC50s of 19.75 nM (HDAC1), 5.63 nM (HDAC2), 40.27 nM (HDAC3), 57.8 nM (HDAC2), 302.73 nM (HDAC8), respectively. HDAC-IN-47 inhibits autophagy and induces apoptosis via the Bax/Bcl-2 and caspase-3 pathways. HDAC-IN-47 arrests cell cycle at G2/M phase, and shows anti-tumor efficacy in vivo .
    HDAC-IN-47
  • HY-B0347S1
    Lacidipine-13C8

    		Apoptosis Caspase Calcium Channel Reactive Oxygen Species Cardiovascular Disease
    Lacidipine- 13C8 is the deuterium labeled Lacidipine[1]. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI)[2][3].
    Lacidipine-13C8
  • HY-B0347S3
    Lacidipine-13C4

    		Calcium Channel Caspase Reactive Oxygen Species Apoptosis Isotope-Labeled Compounds Cardiovascular Disease
    Lacidipine- 13C4 is 13C labeled Lacidipine (HY-B0347). Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) .
    Lacidipine-13C4
  • HY-B0347R
    Lacidipine (Standard)

    		Calcium Channel Reactive Oxygen Species Caspase Apoptosis Cardiovascular Disease
    Lacidipine (Standard) is the analytical standard of Lacidipine. This product is intended for research and analytical applications. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) .
    Lacidipine (Standard)
  • HY-N0702R
    Tenuifolin (Standard)

    		Beta-secretase Cholinesterase (ChE) Neurological Disease
    Tenuifolin (Standard) is the analytical standard of Tenuifolin. This product is intended for research and analytical applications. Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD) .
    Tenuifolin (Standard)
  • HY-168632
    Topoisomerase I/II inhibitor 6

    		Topoisomerase Apoptosis Cancer
    Topoisomerase I/II inhibitor 6 (compound 3i) is a potent inhibitor of topoisomerase I and II with IC50s of 4.77 and 15 µM, respectively. Topoisomerase I/II inhibitor 6 shows antiproliferative activities against human melanoma LOX IMVI cancer cell line with IC50 values of 26.7 and 25.4 µM, respectively. Topoisomerase I/II inhibitor 6 provokes substantial levels of early, late apoptosis and increases the expression level of active caspase-3 .
    Topoisomerase I/II inhibitor 6
  • HY-147504
    Anticancer agent 63

    		Apoptosis Caspase Bcl-2 Family Cancer
    Anticancer agent 63 (compound 3h) shows active in reducing the viability of different cancer cell lines, including SW480, HeLa, A549 and MCF-7, with IC50 values at 24 h of 4.9, 11.5, 9.4, and 3.4 μM, respectively. Anticancer agent 63 induce apoptosis in MCF-7 cells via down-regulating the expression of Bcl-2 and up-regulating the expression of IL-2 and Caspase-3. Anticancer agent 63 also shows antioxidant activity .
    Anticancer agent 63
  • HY-170434
    Bfl-1-IN-6

    		Bcl-2 Family Caspase Cancer
    Bfl-1-IN-6 (Compound 20) is an orally active inhibitor for Bcl-2 related protein A1 (BFL1) with an IC50 of 19 nM. Bfl-1-IN-6 stabilizes BFL1 protein, activates cleaved caspase 3, and exhibits antitumor efficacy in mouse models .
    Bfl-1-IN-6
  • HY-13326
    ASP3026
    5 Publications Verification

    		 Anaplastic lymphoma kinase (ALK) Apoptosis ROS Kinase Caspase PARP IGF-1R STAT Akt JNK Cancer
    ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research .
    ASP3026
  • HY-168483
    FTO-IN-13

    		Apoptosis Fat Mass and Obesity-associated Protein (FTO) Cancer
    FTO-IN-13 (compound 8t) is a potent FTO inhibitor. FTO-IN-13 shows antiproliferative activity. FTO-IN-13 induces apoptosis. FTO-IN-13 decreases the protein expression of Bcl-2 and Caspase 3 active. FTO-IN-13 decreases MYC and CEBPA gene expression. FTO-IN-13 shows anticancer activity .
    FTO-IN-13
  • HY-118304B
    AKN-028 acetate

    		FLT3 Apoptosis Caspase Cancer
    AKN-028 acetate, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM. AKN-028 acetate inhibits FLT3 autophosphorylation. AKN-028 acetate induces dose-dependent cytotoxic response (mean IC50=1 μM). AKN-028 acetate induces apoptosisby activation of caspase 3. AKN-028 acetate can be used in research of acute myeloid leukemia (AML).
    AKN-028 acetate
  • HY-118304
    AKN-028

    		FLT3 Apoptosis Caspase Cancer
    AKN-028, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6?nM. AKN-028 inhibits FLT3 autophosphorylation. AKN-028 induces dose-dependent cytotoxic response (mean IC50=1?μM). AKN-028 induces apoptosisby activation of caspase 3. AKN-028 can be used in research of acute myeloid leukemia (AML) .
    AKN-028
  • HY-118304A
    AKN-028 TFA

    		FLT3 Apoptosis Caspase Cancer
    AKN-028 TFA, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6?nM. AKN-028 TFA inhibits FLT3 autophosphorylation. AKN-028 TFA induces dose-dependent cytotoxic response (mean IC50=1?μM). AKN-028 TFA induces apoptosisby activation of caspase 3. AKN-028 TFA can be used in research of acute myeloid leukemia (AML) .
    AKN-028 TFA
  • HY-119272
    EF24
    1 Publications Verification

    		 ERK Caspase NF-κB Apoptosis p38 MAPK Reactive Oxygen Species Inflammation/Immunology Cancer
    EF24, a curcumin analogue, is an NF-kB inhibitor with great anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 is active against melanoma and breast cancer cell lines with GI50 values of 0.7 μM and 0.8 μM, respectively. EF24 induces cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. EF24 increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK .
    EF24
  • HY-112296
    T025
    2 Publications Verification

    		 CDK Apoptosis DYRK Cancer
    T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .
    T025

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: